BRPI0923556A2 - agente para o tratamento de estenose do canal espinhal - Google Patents

agente para o tratamento de estenose do canal espinhal

Info

Publication number
BRPI0923556A2
BRPI0923556A2 BRPI0923556A BRPI0923556A BRPI0923556A2 BR PI0923556 A2 BRPI0923556 A2 BR PI0923556A2 BR PI0923556 A BRPI0923556 A BR PI0923556A BR PI0923556 A BRPI0923556 A BR PI0923556A BR PI0923556 A2 BRPI0923556 A2 BR PI0923556A2
Authority
BR
Brazil
Prior art keywords
agent
treatment
spinal canal
canal stenosis
stenosis
Prior art date
Application number
BRPI0923556A
Other languages
English (en)
Inventor
Lothar Pache
Rudolf Reiter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0923556A2 publication Critical patent/BRPI0923556A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
BRPI0923556A 2008-12-23 2009-12-22 agente para o tratamento de estenose do canal espinhal BRPI0923556A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172859 2008-12-23
PCT/EP2009/067768 WO2010072774A2 (de) 2008-12-23 2009-12-22 Mittel zur behandlung der spinalkanalstenose

Publications (1)

Publication Number Publication Date
BRPI0923556A2 true BRPI0923556A2 (pt) 2016-01-26

Family

ID=40527906

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923556A BRPI0923556A2 (pt) 2008-12-23 2009-12-22 agente para o tratamento de estenose do canal espinhal

Country Status (11)

Country Link
EP (1) EP2367543A2 (pt)
JP (1) JP2012513446A (pt)
KR (1) KR20110098965A (pt)
CN (1) CN102271667A (pt)
AU (1) AU2009331469A1 (pt)
BR (1) BRPI0923556A2 (pt)
CA (1) CA2748163A1 (pt)
IL (1) IL213768A0 (pt)
MX (1) MX2011006852A (pt)
SG (1) SG172315A1 (pt)
WO (1) WO2010072774A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009405A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo ergolina y usos de estos.
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69919191T2 (de) 1998-09-01 2005-07-28 Nissan Chemical Industries, Ltd. Heilmittel für die stenose des rückenmarkkanals
WO2004043491A1 (ja) 2002-11-14 2004-05-27 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
US20070167403A1 (en) 2003-04-03 2007-07-19 Yoshifumi Takenobu Remedy for spinal canal stenosis
DE102006013307B3 (de) 2006-03-21 2007-10-04 Ergonex Pharma Gmbh Tergurid/Protergurid zur Behandlung von chronischen Schmerzen

Also Published As

Publication number Publication date
KR20110098965A (ko) 2011-09-02
MX2011006852A (es) 2011-07-20
AU2009331469A1 (en) 2011-07-21
IL213768A0 (en) 2011-07-31
EP2367543A2 (de) 2011-09-28
WO2010072774A3 (de) 2010-09-23
JP2012513446A (ja) 2012-06-14
WO2010072774A2 (de) 2010-07-01
SG172315A1 (en) 2011-07-28
CN102271667A (zh) 2011-12-07
CA2748163A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
EP2292231A4 (en) MEDICAMENT FOR TREATING SPINAL STENOSIS
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
PT2894165T (pt) Métodos e composições para o tratamento de distúrbios associados ao complemento
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0920030A2 (pt) agente de oclusão do tecido
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0822625A2 (pt) "dispositivo espaçador modular para o tratamento de infecções por próteses"
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
IL208549A (en) Auris formulations for treating otic diseases and conditions
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0819361A2 (pt) Composição de tratamento de cabelos e agente de tratamento
PT2340042E (pt) Métodos e composições para o tratamento de cancro
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0807730A2 (pt) Método de condicionamento de tecidos e composição sólida para tratamento de tecidos
BRPI0719089A2 (pt) Método de tratamento de tecido e composição para transmitir hidrofobicidade diferencial

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]